Extended Data Fig. 3: Immune subsets versus response to anti-TIGIT/Lag-3.
a. Proportions of circulating lymphocytes (CD8, CD4, Treg and NK cells) in biospecimens obtained from responding (Resp) or non-responding (NR) patients before treatment (PreRx) or after first (C1) or second cycle (C2) of therapy with anti-TIGIT antibody. Data points represent biologically independent samples (TIGIT Resp PreRx: n = 4, TIGIT Resp C1: n = 7, TIGIT Resp C2: n = 4; TIGIT NR Pre Rx: n = 4; TIGIT NR C1: n = 9, TIGIT NR C2: n = 2). Box plots represent median with Q1-Q3 and error bars as min-max. b, c. Proportions of CD4 subsets; naïve (CCR7 + RO-), central memory (CM; CCR7 + RO + ), effector memory (EM; CCR7-RO + ) and terminal effectors (Term EFF; CCR7-RO-) CD4 T cells in blood and bone marrow biospecimens obtained from responding (Resp) or non-responding (NR) patients before treatment (PreRx) or after first (C1) or second cycle (C2) of therapy with anti-LAG3 antibody. Data points represent biologically independent samples. b. Blood CD4 subsets (LAG3 Resp PreRx: n = 4, LAG3 Resp C1: n = 6, LAG3 Resp C2: n = 2; LAG3 NR PreRx: n = 6; LAG3 NR C1: n = 10, LAG3 NR C2: n = 3). There were higher proportions of circulating naïve CD4 and lower proportions of CM CD4 T cells in patients who responded to anti-LAG3 therapy compared to patients who did not respond. Responder Pre+C1 + C2 compared to non-responder Pre+C1 + C2, 2 tailed Mann Whitney. c. Bone marrow CD4 subsets (LAG3 Resp Pre Rx: n = 2, LAG3 Resp C1: n = 2, LAG3 Resp C2: n = 2; LAG3 NR Pre Rx: n = 4; LAG3 NR C1: n = 5, LAG3 NR C2: n = 2). There were higher proportions of bone marrow naïve CD4 T cells in patients who responded to anti-LAG3 therapy compared to patients who did not respond. Responder Pre+C1 + C2 compared to non-responder Pre+C1 + C2, 2 tailed Mann Whitney. Box plots represent median with Q1-Q3 and error bars as min-max.
